EyePoint Pharmaceuticals ... (EYPT)
EyePoint Pharmaceuticals Statistics
Share Statistics
EyePoint Pharmaceuticals has 68.73M shares outstanding. The number of shares has increased by 31.96% in one year.
| Shares Outstanding | 68.73M |
| Shares Change (YoY) | 31.96% |
| Shares Change (QoQ) | 0.7% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 59.62M |
| Failed to Deliver (FTD) Shares | 1.89K |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 10.93M, so 15.9% of the outstanding shares have been sold short.
| Short Interest | 10.93M |
| Short % of Shares Out | 15.9% |
| Short % of Float | 17.96% |
| Short Ratio (days to cover) | 15.48 |
Valuation Ratios
The PE ratio is -3.2 and the forward PE ratio is -2.35. EyePoint Pharmaceuticals's PEG ratio is -0.12.
| PE Ratio | -3.2 |
| Forward PE | -2.35 |
| PS Ratio | 9.69 |
| Forward PS | 0.7 |
| PB Ratio | 1.25 |
| P/FCF Ratio | -3.22 |
| PEG Ratio | -0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for EyePoint Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.81, with a Debt / Equity ratio of 0.06.
| Current Ratio | 7.81 |
| Quick Ratio | 7.77 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.17 |
| Interest Coverage | -10418.14 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $262.26K |
| Profits Per Employee | $-793.15K |
| Employee Count | 165 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 1.61 |
Taxes
| Income Tax | 90K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -59.26% in the last 52 weeks. The beta is 1.41, so EyePoint Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | -59.26% |
| 50-Day Moving Average | 6.02 |
| 200-Day Moving Average | 8.15 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 851.23K |
Income Statement
In the last 12 months, EyePoint Pharmaceuticals had revenue of 43.27M and earned -130.87M in profits. Earnings per share was -2.32.
| Revenue | 43.27M |
| Gross Profit | 39.56M |
| Operating Income | -145.85M |
| Net Income | -130.87M |
| EBITDA | -129.23M |
| EBIT | -130.77M |
| Earnings Per Share (EPS) | -2.32 |
Balance Sheet
The company has 99.7M in cash and 21.86M in debt, giving a net cash position of 77.85M.
| Cash & Cash Equivalents | 99.7M |
| Total Debt | 21.86M |
| Net Cash | 77.85M |
| Retained Earnings | -873.02M |
| Total Assets | 418.46M |
| Working Capital | 334.26M |
Cash Flow
In the last 12 months, operating cash flow was -126.23M and capital expenditures -4.05M, giving a free cash flow of -130.28M.
| Operating Cash Flow | -126.23M |
| Capital Expenditures | -4.05M |
| Free Cash Flow | -130.28M |
| FCF Per Share | -2.31 |
Margins
Gross margin is 91.42%, with operating and profit margins of -337.06% and -302.43%.
| Gross Margin | 91.42% |
| Operating Margin | -337.06% |
| Pretax Margin | -302.22% |
| Profit Margin | -302.43% |
| EBITDA Margin | -298.63% |
| EBIT Margin | -337.06% |
| FCF Margin | -301.06% |
Dividends & Yields
EYPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EYPT is $29, which is 332.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $29 |
| Price Target Difference | 332.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Dec 9, 2020. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 9, 2020 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 0.31 |
| Piotroski F-Score | 3 |